Balanced oxidative status by nesfatin-1 in intestinal ischemia-reperfusion

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 3, 2015, Pages 3318-3324

  Ayada, Ceylan ^a   Toru, Ümran ^a   Genç, Osman ^a   Akcılar, Raziye ^a   Şahin, Server ^a  

^a DUMLUPINAR UNIVERSITY   (Turkey)

Author keywords

Endothelin 1; ENOS; Ischemia reperfusion; Nesfatin 1; Total antioxidant capacity; Total oxidant capacity

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; NESFATIN 1; NEUROPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; COLORIMETRY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; INTESTINE ISCHEMIA; LAPAROTOMY; MALE; NONHUMAN; OXIDATIVE STRESS; OXIDATIVE STRESS INDEX; PARAMETERS; RAT; REPERFUSION; REPERFUSION INJURY;

RATTUS; TOSCANA VIRUS;

EID: 84929192347     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Tullis MJ, Brown S, Gewertz BL. Hepatic influence on pulmonary neutrophil sequestration following intestinal ischemia-reperfusion. J Surg Res 1996; 66: 143-6.
2. Mallick IH, Yang W, Winslet MC, Seifalian AM. Ischemia-reperfusion injury of the intestine and protective strategies against injury. Dig Dis Sci 2004; 49: 1359-77.
3. Collard CD, Gelman S. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology 2001; 94: 1133-8.
4. Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. J Pathol 2000; 190: 255-66.
5. Cowley MA, Grove KL. To be or NUCB2, is nesfatin the answer? Cell Metab 2006; 4: 421-2.
6. Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto K, Tsuchiya T, Monden T, Horiguchi K, Yamada M, Mori M. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006; 443: 709-12.
7. García-Galiano D, Navarro VM, Gaytan F, Tena-Sempere M. Expanding roles of NUCB2/nesfatin-1 in neuroendocrine regulation. J Mol Endocrinol 2010; 45: 281-90.
8. Yamawaki H, Takahashi M, Mukohda M, Morita T, Okada M, Hara Y. A novel adipocytokine, nesfatin-1 modulates peripheral arterial contractility and blood pressure in rats. Biochem Biophys Res Commun 2012; 418: 676-81.
9. Ayada C, Turgut G, Turgut S, Güçlü Z. The eff-ect of chronic peripheral nesfatin-1 application on blood pressure in normal and chronic restraint stressed rats: related with circulating level of blood pressure regulators. Gen Physiol Biophys..
10. Angelone T, Filice E, Pasqua T, Amodio N, Galluccio M, Montesanti G, Quintieri AM, Cerra MC. Nesfatin-1 as a novel cardiac peptide: identification, functional characterization, and protection against ischemia/reperfusion injury. Cell Mol Life Sci 2013; 70: 495-509.
11. Rocha Bda C, Mendes RR, Lima GV, Albuquerque Gde S, Araújo LL, de Jesus MN, Dos Santos WL, Carreiro MC. Experimental model of mesenteric ischemia: reperfusion by abdominal aorta clamping in Wistar rats. Rev Col Bras Cir 2012; 39: 207-10.
12. Shimizu H, Oh-I S, Hashimoto K, Nakata M, Yamamoto S, Yoshida N, Eguchi H, Kato I, Inoue K, Satoh T, Okada S, Yamada M, Yada T, Mori M. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-in-dependent mechanism. Endocrinology 2009; 150: 662-71.
13. Kosecik M, Erel O, Sevinc E, Selek S. Increased oxidative stress in children exposed to passive smoking. Int J Cardiol 2005; 100: 61-4.
14. Nakata M, Manaka K, Yamamoto S, Mori M, Yada T. Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca (2+) influx through L-type channels in mouse islet β-cells. Endocr J 2011; 58: 305-13.
15. Agapitov AV, Haynes WG. Role of endothelin in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2002; 3: 1-15.
16. Ozel SK, Yüksel M, Haklar G, Durakbaşa CU, Dagli TE, Aktan AO. Nitric oxide and endothelin relationship in intestinal ischemia/reperfusion injury (II). Prostaglandins Leukot Essent Fatty Acids 2001; 64: 253-7.
17. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109 Suppl 1: 327-32.
18. Rubbo H, Trostchansky A, Botti H, Batthyány C. Interactions of nitric oxide and peroxynitrite with low-density lipoprotein. Biol Chem 2002; 383: 547-52.
19. Kleinbongard P, Schulz R, Rassaf T, Lauer T, Dejam A, Jax T, Kumara I, Gharini P, Kabanova S, Ozüyaman B, Schnürch HG, Gödecke A, Weber AA, Robenek M, Robenek H, Bloch W, Rösen P, Kelm M. Red blood cells express a functional endothelial nitric oxide synthase. Blood 2006; 107: 2943-51.
20. Darley-Usmar V, Wiseman H, Halliwell B. Nitric oxide and oxygen radicals: a question of balance. FEBS Lett 1995; 369: 131-5.
21. Wedgwood S, Black SM. Endothelin-1 decreases endothelial NOS expression and activity through ETA receptor-mediated generation of hydrogen peroxide. Am J Physiol Lung Cell Mol Physiol 2005; 288: L480-7.
22. Durakbasa CU, Dagli TE, Mouni H, Haklar G, Bilsel AS, Yuksel M, Aktan AO. Nitric oxide and endothelin relationship in intestinal ischemia/reperfusion injury. Prostaglandins Leukot Ess-ent Fatty Acids 1998; 59: 379-83.
23. Özsavcí D, Erşahin M, Şener A, Özakpinar ÖB, Toklu HZ, Akakín D, Şener G, Yeğen BÇ. The novel function of nesfatin-1 as an anti-inflammatory and antiapoptotic peptide in subarachnoid hemorrhage-induced oxidative brain damage in rats. Neurosurgery 2011; 68: 1699-708; discussion 1708.